Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression
- PMID: 10799995
- DOI: 10.1002/(sici)1097-0290(20000620)68:6<689::aid-bit13>3.0.co;2-a
Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression
Abstract
A recombinant, multifunctional protein has been designed for optimized, cell-targeted DNA delivery and gene expression in mammalian cells. This hybrid construct comprises a viral peptide ligand for integrin alpha(V)beta(3) binding, a DNA-condensing poly-L-lysine domain, and a complete, functional beta-galactosidase protein that serves simultaneously as purification tag and DNA-shielding agent. This recombinant protein is stable; it has been produced successfully in Escherichia coli and can be purified in a single step by affinity chromatography. At optimal molar ratios, mixtures of this vector and a luciferase-reporter plasmid form stable complexes that transfect cultured cells. After exposure to these cell-targeted complexes, steady levels of gene expression are observed for more than 3 days after transfection, representing between 20 and 40% of those achieved with untargeted, lipid-based DNA-condensing agents. The principle to include viral motifs for cell infection in single polypeptide recombinant proteins represents a promising approach towards the design of non-viral modular DNA transfer vectors that conserve the cell-target- ing specificity of native viruses and that do not need further processing after bioproduction in a recombinant host.
Copyright 2000 John Wiley & Sons, Inc.
Similar articles
-
Recombinant fusion proteins TAT-Mu, Mu and Mu-Mu mediate efficient non-viral gene delivery.J Gene Med. 2007 Apr;9(4):275-86. doi: 10.1002/jgm.1014. J Gene Med. 2007. PMID: 17397090
-
The position of the heterologous domain can influence the solubility and proteolysis of beta-galactosidase fusion proteins in E. coli.J Biotechnol. 1996 Jul 31;48(3):191-200. doi: 10.1016/0168-1656(96)01508-8. J Biotechnol. 1996. PMID: 8861998
-
Adenovirus-assisted lipofection: efficient in vitro gene transfer of luciferase and cytosine deaminase to human smooth muscle cells.Atherosclerosis. 1996 Jul;124(1):49-60. doi: 10.1016/0021-9150(96)05816-9. Atherosclerosis. 1996. PMID: 8800493
-
Improved cationic lipid formulations for in vivo gene therapy.Ann N Y Acad Sci. 1995 Nov 27;772:126-39. doi: 10.1111/j.1749-6632.1995.tb44738.x. Ann N Y Acad Sci. 1995. PMID: 8546385 Review.
-
Inducible vectors for expression in mammalian cells.Curr Opin Biotechnol. 1992 Oct;3(5):506-11. doi: 10.1016/0958-1669(92)90078-w. Curr Opin Biotechnol. 1992. PMID: 1368935 Review.
Cited by
-
Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector.BMC Neurosci. 2006 Apr 25;7:35. doi: 10.1186/1471-2202-7-35. BMC Neurosci. 2006. PMID: 16638118 Free PMC article.
-
DNA vaccines: improving expression of antigens.Genet Vaccines Ther. 2003 Sep 16;1(1):2. doi: 10.1186/1479-0556-1-2. Genet Vaccines Ther. 2003. PMID: 14606963 Free PMC article.
-
Controlled release from recombinant polymers.J Control Release. 2014 Sep 28;190:304-13. doi: 10.1016/j.jconrel.2014.06.016. Epub 2014 Jun 21. J Control Release. 2014. PMID: 24956486 Free PMC article. Review.
-
Comparative analysis of lentiviral vectors and modular protein nanovectors for traumatic brain injury gene therapy.Mol Ther Methods Clin Dev. 2014 Oct 15;1:14047. doi: 10.1038/mtm.2014.47. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015985 Free PMC article.
-
Development of recombinant cationic polymers for gene therapy research.Adv Drug Deliv Rev. 2010 Dec 30;62(15):1524-9. doi: 10.1016/j.addr.2010.04.001. Epub 2010 Apr 14. Adv Drug Deliv Rev. 2010. PMID: 20399239 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources